LAVA Therapeutics cancels EGM for XOMA acquisition, reconvenes by early Nov

LAVA Therapeutics NV

EGM scheduled for Sept 30, 2025 cancelled; reconvened by early November 2025.
Cancellation due to ongoing discussions with XOMA on cash forecast and consideration payable.
Votes already cast will not count; shareholders must revote as of new record date.
Both LAVA and XOMA remain committed to completing the transaction in Q4 2025.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.